Genetic Aberrations in IPSCs Are Introduced by a Transient G1/S Cell Cycle Checkpoint Deficiency
Overview
Authors
Affiliations
A number of point mutations have been identified in reprogrammed pluripotent stem cells such as iPSCs and ntESCs. The molecular basis for these mutations has remained elusive however, which is a considerable impediment to their potential medical application. Here we report a specific stage at which iPSC generation is not reduced in response to ionizing radiation, i.e. radio-resistance. Quite intriguingly, a G1/S cell cycle checkpoint deficiency occurs in a transient fashion at the initial stage of the genome reprogramming process. These cancer-like phenomena, i.e. a cell cycle checkpoint deficiency resulting in the accumulation of point mutations, suggest a common developmental pathway between iPSC generation and tumorigenesis. This notion is supported by the identification of specific cancer mutational signatures in these cells. We describe efficient generation of human integration-free iPSCs using erythroblast cells, which have only a small number of point mutations and INDELs, none of which are in coding regions.
Exploring human pancreatic organoid modelling through single-cell RNA sequencing analysis.
Cherubini A, Rusconi F, Piras R, Wachtershauser K, Dossena M, Barilani M Commun Biol. 2024; 7(1):1527.
PMID: 39558019 PMC: 11574267. DOI: 10.1038/s42003-024-07193-3.
Araki R, Suga T, Hoki Y, Imadome K, Sunayama M, Kamimura S Nat Commun. 2024; 15(1):4946.
PMID: 38862540 PMC: 11166658. DOI: 10.1038/s41467-024-49335-5.
Babini H, Jimenez-Sabado V, Stogova E, Arslanova A, Butt M, Dababneh S Front Cell Dev Biol. 2024; 12:1298007.
PMID: 38304423 PMC: 10830749. DOI: 10.3389/fcell.2024.1298007.
HLA-based banking of induced pluripotent stem cells in Saudi Arabia.
Alowaysi M, Lehmann R, Al-Shehri M, Baadhaim M, Alzahrani H, Aboalola D Stem Cell Res Ther. 2023; 14(1):374.
PMID: 38111036 PMC: 10729375. DOI: 10.1186/s13287-023-03612-0.
Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.
PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.